Trials included in final NMAs
|
ECOG 1697 [22]
|
Agarwala et al. (2017)
|
NCT00003641
|
IFN alfa-2b (high-dose)
|
Observation
|
NA
|
Open-label
|
III
|
Yes
|
Australia, Canada, South Africa, USA
|
Scottish study [23]
|
Cameron et al. (2001)
|
NA
|
IFN alfa-2b (low-dose)
|
Observation
|
NA
|
Open-label
|
NR
|
Yes
|
Scotland
|
WHO Melanoma Programme Trial 16 [24]
|
Cascinelli et al. (2001)
|
NA
|
IFN alfa-2b (low-dose)
|
Observation
|
NA
|
Open-label
|
NR
|
Yes
|
Italy
|
EORTC 18071 [25]
|
Eggermont et al. (2015)
|
NCT00636168
|
Ipilimumab
|
Placebo
|
NA
|
Double-blind
|
III
|
Yes
|
Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, USA
|
EORTC 18952 [26]
|
Eggermont et al. (2005)
|
NA
|
IFN alfa-2b (high-dose/ 13 months)
|
IFN alfa-2b (low-dose/ 25 months)
|
Observation
|
Open-label
|
III
|
Yes
|
Austria, Belgium, Bulgaria, Croatia, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Poland, Portugal, Russia, Serbia and Montenegro, Slovakia, Spain, Sweden, Switzerland, Netherlands, Turkey, United Kingdom
|
EORTC 18991 [27]
|
Eggermont et al. (2008)
|
NCT00006249
|
PEG IFN alfa-2b
|
Observation
|
NA
|
Open-label
|
III
|
Yes
|
Australia, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Israel, Italy, Netherlands, Poland, Portugal, Slovenia, Spain, Switzerland, Turkey, United Kingdom
|
KEYNOTE-054 [28, 29]
|
Eggermont et al. (2018)
|
NCT02362594
|
Pembrolizumab
|
Placebo
|
NA
|
Double-blind
|
III
|
Yes
|
Australia, Belgium, Canada, Denmark, Finland, France, Germany, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Poland, Portugal, Russian Federation, Serbia, Spain, Sweden, Switzerland, United Kingdom, USA
|
S0008 [30]
|
Flaherty et al. (2014)
|
NCT00006237
|
IFN alfa-2b (high-dose)
|
Other chemotherapy
|
NA
|
Open-label
|
III
|
Yes
|
Australia, USA
|
Garbe 2008 (DeCOG) [31]
|
Garbe et al. (2008)
|
NA
|
IFN alfa-2a (low-dose)
|
IFN alfa-2a + dacarbazine
|
Observation
|
Open-label
|
III
|
Yes
|
Germany, Switzerland
|
AIM HIGH Study [32]
|
Hancock et al. (2004)
|
NA
|
IFN alfa-2a (low-dose)
|
Observation
|
NA
|
Open-label
|
III
|
Yes
|
United Kingdom
|
Nordic IFN Trial [33]
|
Hansson et al. (2011)
|
NCT01259934
|
IFN alfa-2b (1 year)
|
IFN alfa-2b (2 years)
|
Observation
|
Open-label
|
III
|
Yes
|
Denmark, Finland, Norway, Sweden
|
Kim et al. 2009 [34]
|
–
|
NA
|
Cisplatin, vinblastine, dacarbazine, IFN alfa-2b, interleukin-2
|
IFN alfa-2b (high-dose)
|
IFN alfa-2b (low-dose)
|
Open-label
|
III
|
NR
|
USA
|
ECOG 1690 [35]
|
Kirkwood et al. (2000)
|
NA
|
IFN alfa-2b (low-dose)
|
IFN alfa-2b (high-dose)
|
Observation
|
Open-label
|
III
|
Yes
|
USA
|
ECOG 1684 [10]
|
Kirkwood et al. (1996)
|
NA
|
IFN alfa-2b (high-dose)
|
Observation
|
NA
|
Open-label
|
III
|
Yes
|
USA
|
EORTC 18871 [36]
|
Kleeberg et al. (2004)
|
NA
|
rIFN alfa-2b
|
Observation
|
NA
|
Open-label
|
III
|
Yes
|
Austria, Belgium, Czech Republic, Estonia, France, Germany, Great Britain, Greece, Israel, Poland, Spain, Switzerland, Yugoslavia
|
COMBI-AD [7, 37]
|
Long et al. (2017)
|
NCT01682083
|
Dabrafenib + trametinib
|
Placebo
|
NA
|
Double-blind
|
III
|
Yes
|
Argentina, Australia, Austria, Belgium, Brazil, Canada, Czech Republic, Denmark, France, Germany, Greece, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Poland, Russia, Spain, Sweden, Switzerland, Taiwan, United Kingdom, USA
|
Stadler et al. (2006) [38]
|
–
|
NA
|
Dacarbazine + natural human IFN alfa
|
Observation
|
NA
|
Open-label
|
NR
|
Yes
|
Germany
|
E1609 [39]
|
Tarhini et al. (2017)
|
NCT01274338
|
Ipilimumab (high-dose)
|
Ipilimumab (low-dose)
|
IFN alfa-2b (high-dose)
|
Open-label
|
III
|
Yes
|
Canada, USA
|
CheckMate 238 [15, 40]
|
Weber et al. (2017)
|
NA
|
Nivolumab
|
Ipilimumab
|
NA
|
Double-blind
|
III
|
Yes
|
Argentina, Australia, Austria, Belgium, Canada, Czech Republic, Finland, France, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Netherlands, Norway, Poland, Romania, South Africa, Spain, Sweden, Switzerland, Taiwan, United Kingdom, USA
|
Trials excluded from final NMAs
|
Eigentler et al. 2016 (DeCOG) [41]
|
Eigentler et al. (2016)
|
NCT00204529
|
PEG IFN alfa-2a
|
IFN alfa-2a (low-dose)
|
NA
|
Open-label
|
III
|
Yes
|
Austria, Germany
|
EADO study [42]
|
Grob et al. (2013)
|
NCT00221702
|
PEG IFN alfa-2b
|
IFN alfa-2b (low-dose)
|
NA
|
Open-label
|
III
|
Yes
|
Austria, France, Germany
|
Lian et al. (2013) [43]
|
–
|
NA
|
IFN alfa-2b (high-dose)
|
Chemotherapy
|
Observation
|
NR
|
II
|
No
|
China
|
Sunbelt Melanoma Trial [44]
|
McMasters et al. (2016)
|
NA
|
IFN alfa-2b (high-dose)
|
Observation
|
NA
|
Open-label
|
III
|
Yes
|
Canada, USA
|
MM-ADJ-5 [45]
|
Mohr et al. (2015)
|
NCT00226408
|
IFN alfa-2b (high-dose)
|
IFN alfa-2b (intermittent high-dose)
|
NA
|
Open-label
|
III
|
Yes
|
Austria, Germany, Greece, Switzerland
|
Tobin et al. (2018) [46]
|
–
|
NCT02403778
|
Ipilimumab
|
Ipilimumab plus ATRA
|
NA
|
Open-label
|
II
|
No
|
USA
|
Wang et al. (2015) [47]
|
–
|
NA
|
IFN alfa-2b (high-dose)
|
Observation
|
NA
|
Open-label
|
II
|
No
|
China
|